Mycophenolate Mofetil 吗替麦考酚酯


描述

Mycophenolate Mofetil 吗替麦考酚酯

产品标签

Mycophenolic Acid (MPA) 霉酚酸;Immunosuppressive Drug 免疫抑制剂;Inosine monophosphatase dehydrogenase 次黄嘌呤单核苷酸脱氢酶;IMPDH Inhibitor; Mycophenolate mofetil 吗替麦考酚酯;CAS NO:128794-94-5;

产品信息

产品名称 产品编号 CAS NO.          规格           价格(元) 
Mycophenolate Mofetil 吗替麦考酚酯 MZ9232-0100MG    128794-94-5 100mg 598
Mycophenolate Mofetil 吗替麦考酚酯 MZ9232-0500MG 128794-94-5 500mg 1788
Mycophenolate Mofetil 吗替麦考酚酯    MZ9232-1000MG 128794-94-5 1g 2698

产品描述

吗替麦考酚酯(Mycophenolate Mofetil,MMF, CAS:128794-94-5),又名霉酚酸酯,是活体免疫抑制剂霉酚酸(MPA,CAS:24280-93-1)的酯类前药。MMF是一种非竞争性、选择性且可逆的次黄嘌呤单核苷酸脱氢酶(IMPDH)抑制剂,体外无细胞实验MMF对IMPDH I/II的IC50分别是39/27nM。淋巴细胞中对IMPDH的抑制,阻断GTP的从头合成并引起RNA和DNA合成的减少,从而防止淋巴细胞增殖和活化,并抑制抗体生成。这一免疫抑制活性使其在器官移植和自身免疫疾病(如狼疮)发挥积极作用。MMF能抑制I型胶原表达,改善MMP-1表达,并降低α-平滑肌肌动蛋白基因表达。

产品特性

1)CAS NO:128794-94-5

2)化学名:6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4E-hexenoic acid, 2-(4-morpholinyl)ethyl ester

3)同义名:MMF; RS61443; Linfonex; Cellcept®;

4)分子式:C23H31NO7

5)分子量:433.49

6)纯度:≥98%

7)外观:白色或类白色结晶性粉末

8)溶解性:溶于甲醇,DMSO(20mg/ml),无水乙醇(1.4mg/ml),微溶于乙醚,几乎不溶于水

9)化学结构图:

保存与运输方法

保存:室温干燥保存,或置于-20ºC长期干燥保存,至少2年有效。

运输:室温运输。

注意事项

1)本吗替麦考酚酯(MMF)不是临床药物,只能用于科研用途,不能用于诊断或临床用途。

2)为了您的安全和健康,请穿实验服并戴一次性手套操作。

使用方法【源自文献,仅作参考】

文献1,Nakanishi T et al. Effect of the inosine 5′-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol. 2010 Jan;10(1):91-7. PMID: 19840872

体内研究:

动物模型(Animal Model):Lewis rats with abdominal vascularized heterotopic cardiac transplantation

药物配制(Preparation):Mycophenolate mofetil (MMF) was suspended in 0.5% methylcellulose water.

注射剂量(Dosages):Beginning on the operation day,MMF (vehicle control,5, 10, 15, 20 and 40mg/kg) were orally administered once daily for 14 consecutive days. After transplantation, cardiac allograft function was assessed by daily palpation for 28 days, and graft rejection was defined as the cessation of palpable cardiac graft beats.

给药途径(Administration):Oral (p.o.)

文献2,von Vietinghoff S et al. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol. 2011 May 24;57(21):2194-204. PMID: 21596236

体内研究:

动物模型(Animal Model):Young and aged Apoe−/− mice

注射剂量(Dosages):Mycophenolate as the prodrug mycophenolate mofetil was incorporated into high fat diet without cholate (405 of kcal from fat, 1.5% Cholesterol) to reach an oral dose of 30mg/kg body weight*day at a chow consumption of 0.1g/g body-weight.

给药途径(Administration):Oral (p.o.)

相关产品

货号 名称 规格
MZ9231-0100MG     Mycophenolic Acid (MPA) 霉酚酸(麦可酚酸)   100mg     
MZ9232-0100MG Mycophenolate mofetil 吗替麦考酚酯 100mg